Beam Therapeutics (BEAM) said Sunday new data for its engineered stem cell antibody evasion conditioning platform showed that conditioning and in vivo selection with an anti-CD117 antibody allowed engraftment of base-edited hematopoietic stem cells in a non-human primate model.
Engraftment is the process under which transplanted stem cells enter the bloodstream, reach the bone marrow, and produce new blood cells.
The data also showed the inducement of "robust, durable production of fetal hemoglobin," the company said.
Beam Therapeutics said its platform uses two investigational drug products to provide a non-genotoxic alternative to traditional transplant medicines: the BEAM-103 antibody and the BEAM-104 cell therapy. The company plans to advance the two candidates in sickle cell disease and beta-thalassemia, which are blood disorders.
BEAM-103 dosing was well tolerated, with no need for antibiotics or additional supportive care, the company said.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。